<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010390040</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010390040</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics and Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Standardized Visual Predictive Check Versus Visual Predictive Check for Model Evaluation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Diane D.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Shuzhong</given-names></name>
<degrees>PhD</degrees>
</contrib>
<aff id="aff1-0091270010390040">Pfizer Oncology, San Diego, California</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0091270010390040">Diane D. Wang, PhD, Pfizer Oncology, 10646 Science Center Drive, San Diego, CA 92121; e-mail: <email>diane.wang@pfizer.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>54</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>4</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>10</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>The visual predictive check (VPC) is a commonly used approach in model evaluation. However, it may not be feasible to conduct a VPC, or the results of a VPC could be misleading in certain situations. The objectives of the present study were to (1) examine the performance and applicability of the VPC and (2) propose the standardized visual predictive check (SVPC) as an alternative/complementary approach to the VPC. The difference between the SVPC and normalized prediction distribution error (npde) as visual tools for model evaluation is also discussed. The results of the simulation studies demonstrate that the VPC is not appropriate when stratification of covariate(s) in a model is difficult or arbitrary and may not be feasible when study design varies during a study/among participants. The SVPC addresses these issues by displaying the percentiles (P<sub>i,j</sub>) of each participant’s observations in the marginal distribution of the corresponding model-simulated endpoints as a function of time (or any covariate of interest) based on that participant’s own design template. Since the calculation of P<sub>i,j</sub> factors out subject-specific design features, the difference between observation and simulated values is only caused by misspecification of the structure model and/or inadequate estimation of random effect. Thus, the SVPC can be used in any situation.</p>
</abstract>
<kwd-group>
<kwd>pharmacokinetics</kwd>
<kwd>pharmacodynamics</kwd>
<kwd>model evaluation</kwd>
<kwd>visual predictive check</kwd>
<kwd>standardized visual predictive check</kwd>
<kwd>prediction discrepancy</kwd>
<kwd>normalized prediction distribution error</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation have been increasingly used in drug development programs to describe the pharmacokinetics and pharmacodynamics, evaluate mechanistic hypotheses, and understand the sources of PK and PD variability of a study drug.<sup><xref ref-type="bibr" rid="bibr1-0091270010390040">1</xref>–<xref ref-type="bibr" rid="bibr3-0091270010390040">3</xref></sup> The ultimate goal is to select an appropriate dosing regimen, optimize clinical trial design, and make informed go/no-go decisions. The focus of modeling and simulation has been therefore shifted from a model’s descriptive ability to its predictive capability. Model evaluation has thus become one of the most important aspects of model development.<sup><xref ref-type="bibr" rid="bibr4-0091270010390040">4</xref></sup></p>
<p>In addition to basic diagnostics such as evaluation of goodness-of-fit plots, uncertainty of population parameter estimates, and model sensitivity, advanced model evaluation approaches have been developed in the past several years and are increasingly used to evaluate the predictability of a model. These approaches include data splitting, resampling techniques, and Monte Carlo simulation.<sup><xref ref-type="bibr" rid="bibr4-0091270010390040">4</xref>,<xref ref-type="bibr" rid="bibr5-0091270010390040">5</xref></sup> Among the major simulation approaches, including the visual predictive check (VPC),<sup><xref ref-type="bibr" rid="bibr6-0091270010390040">6</xref></sup> numerical predictive check (NPC),<sup><xref ref-type="bibr" rid="bibr5-0091270010390040">5</xref></sup> posterior predictive check (PPC),<sup><xref ref-type="bibr" rid="bibr7-0091270010390040">7</xref></sup> and normalized prediction distribution error (npde),<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref>,<xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> the VPC is the most intuitive and commonly used approach. As indicated by Karlsson et al,<sup><xref ref-type="bibr" rid="bibr5-0091270010390040">5</xref></sup> there are situations where a VPC may not be feasible or can not be correctly performed. Examples of such situations are as follows: (1) patients receive individualized doses or the number of patients per dose group is too small, and the PK or PD model is nonlinear. Therefore, the observations cannot be dose-normalized to conduct a VPC for observations across doses. (2) There are multiple categorical covariate effects on PK or PD parameters so that intensive stratification of data (stratify the data based on the same set of covariate values) may make diagnostics uninformative as the number of graphs increases and the amount of data per graph diminishes. (3) A covariate is a continuous variable that makes data stratification difficult or arbitrary. (4) Study design and execution vary among individuals, such as adaptive design, difference in dosing schedules, variation in dosing time, changes in dose and dosing schedule during a study, and protocol violations. (5) There are different concomitant medications and food intake among individuals when there are drug-drug interactions and a food effect on PK.</p>
<p>In this article, we propose the standardized visual predictive check (SVPC) as an alternative approach to the VPC. The SVPC provides similar information as a VPC but displays observations and predictions on a standardized scale, which addresses the problems of the VPC and is applicable in all above-mentioned situations where a VPC cannot be used. We discuss the methodology and show several examples of its applications. We illustrate how a VPC is inadequate or is not feasible in many cases, whereas an SVPC can be used in all situations.</p>
<p>An additional discussion point is the similarity and difference between the SVPC and the npde. The npde is a model evaluation approach proposed by Brendel et al<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref></sup> and Comets et al<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> and is an improved version of predictive discrepancy (pd).<sup><xref ref-type="bibr" rid="bibr10-0091270010390040">10</xref></sup> The npde takes into account the full predictive distribution of each individual observation and handles multiple observations within a subject by a de-correlation process. If a model describes the data well, an npde should follow the standard normal distribution. Neither pd nor npde was intended/recommended for evaluation of model predictions over a time course in place of a VPC but rather provides a global test of consistency of the entire data for an assumed model.</p>
<sec id="section1-0091270010390040" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010390040">
<title>Population PK and PD Models</title>
<p>Given here is a general form of mixed-effect models that has been used to describe the PK or PD of either a drug candidate under development or a hypothetical drug. The <italic>j</italic>th observation for the <italic>i</italic>th individual (<italic>y</italic><sub><italic>ij</italic></sub>) as a function of time (<italic>t</italic><sub><italic>ij</italic></sub>) is given by</p>
<p><disp-formula id="disp-formula1-0091270010390040">
<mml:math display="block" id="math1-0091270010390040">
<mml:mrow>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>f</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010390040" xlink:href="10.1177_0091270010390040-eq1.tif"/>
</disp-formula></p>
<p>where θ<sub><italic>i</italic></sub> is a set of the PK or PD parameters for the <italic>i</italic>th individual, and ε<sub>1<italic>ij</italic></sub> and ε<sub>2<italic>ij</italic></sub> are intrasubject variability normally distributed with a mean of zero and variance of <inline-formula id="inline-formula1-0091270010390040">
<mml:math display="inline" id="math2-0091270010390040">
<mml:mrow>
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mn>1</mml:mn>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula2-0091270010390040">
<mml:math display="inline" id="math3-0091270010390040">
<mml:mrow>
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mn>2</mml:mn>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, respectively. θ<sub><italic>i</italic></sub> is further described by</p>
<p><disp-formula id="disp-formula2-0091270010390040">
<mml:math display="block" id="math4-0091270010390040">
<mml:mrow>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>z</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>η</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010390040" xlink:href="10.1177_0091270010390040-eq2.tif"/>
</disp-formula></p>
<p>where <italic>z</italic><sub><italic>i</italic></sub> is a set of fixed effects, θ is a set of typical population PK/PD parameters, and η<italic><sub>i</sub></italic> is the intersubject variability with a mean of zero and variance of Ω<sup>2</sup>. Modeling and simulation studies were conducted using NONMEM (version VI; GloboMax, Hanover, Maryland). Data processing and graphical presentation were conducted using S-PLUS 7.0 (TIBCO, Palo Alto, California).</p>
</sec>
<sec id="section3-0091270010390040">
<title>Visual Predictive Check</title>
<p>The VPC is often performed during the model-building process to evaluate the predictability of the model. It compares the statistics (eg, median and the 90th percentile interval) of the observations and model-simulated predictions that are calculated from the entire data set (all participants) at each time point.<sup><xref ref-type="bibr" rid="bibr6-0091270010390040">6</xref>,<xref ref-type="bibr" rid="bibr11-0091270010390040">11</xref></sup> Simulation is based on the final model, including both fixed (eg, covariate effect) and random effects. In this article, 1000 simulations were conducted for each model evaluated using the original data set by setting NSUBPROBLEMS = 1000 in NONMEM.</p>
</sec>
<sec id="section4-0091270010390040">
<title>Standardized Visual Predictive Check</title>
<p>The SVPC displays the percentile of each observation of each participant in the marginal distribution of model-simulated endpoints (<italic>P<sub>i,j</sub></italic>) as a function of time (or any covariate of interest) using that participant’s own design template. The design template refers to the dose, dosing schedule, values of influential covariates, and so on for a specific participant. The SVPC was developed to address the situations where the VPC would not be feasible. The key idea is to compare each participant’s observations to the model-simulated values based on his or her own design template. By this approach, the differences between the observed and model-simulated values are caused only by structural model misspecification and/or inadequate estimation of the inter- and intrasubject variability.</p>
<p>To implement the SVPC, 1000 data sets are simulated using the final model based on the original data set (the data set used for model development) by setting NSUBPROBLEMS = 1000 in NONMEM. Therefore, 1000 sets of values are simulated for each participant based on this participant’s design template. The percentile (<italic>P</italic><sub><italic>i,j</italic></sub>) of the <italic>j</italic>th observation for the <italic>i</italic>th participant is calculated by</p>
<p><disp-formula id="disp-formula3-0091270010390040">
<mml:math display="block" id="math5-0091270010390040">
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mn>1</mml:mn>
<mml:mrow>
<mml:mn>1000</mml:mn>
</mml:mrow>
</mml:mfrac>
<mml:munderover>
<mml:mstyle displaystyle="true" mathsize="140%">
<mml:mo>∑</mml:mo>
</mml:mstyle>
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mrow>
<mml:mn>1000</mml:mn>
</mml:mrow>
</mml:munderover>
<mml:msub>
<mml:mi>δ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>n</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010390040" xlink:href="10.1177_0091270010390040-eq3.tif"/>
</disp-formula></p>
<p>where δ<sub><italic>ij,n</italic></sub> = 1 if <inline-formula id="inline-formula3-0091270010390040">
<mml:math display="inline" id="math6-0091270010390040">
<mml:mrow>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>&gt;</mml:mo>
<mml:msub>
<mml:msup>
<mml:mi>y</mml:mi>
<mml:mo>′</mml:mo>
</mml:msup>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>n</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> (otherwise, δ<sub><italic>ij,n</italic></sub> = 0), y<sub><italic>ij</italic></sub> is the actual <italic>j</italic>th observation for the <italic>i</italic>th individual, and <italic>y</italic>′<sub><italic>ij,n</italic></sub> is the <italic>n</italic>th simulated observation corresponding to <italic>y</italic><sub><italic>ij</italic></sub>. <italic>P</italic><sub><italic>i,j</italic></sub> values are then plotted against time. Since the <italic>P</italic><sub><italic>i,j</italic></sub> values do not contain subject-specific design template information, they can be plotted on the same plot regardless of the difference in participants’ design templates. In contrast to npde, in which de-correlation between multiple observations within each participant is performed,<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref>,<xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> no de-correlation is performed in an SVPC since the focus is to evaluat<italic>e</italic> the <italic>P<sub>i,j</sub></italic> distribution along the time course, and there is only 1 observation at each time point for a participant. For a model that has adequately characterized both fixed effect and random effects, <italic>P</italic><sub><italic>i,j</italic></sub> should be uniformly distributed between 0 and 1 at any given time point or within a small time interval. A deviation from uniformity indicates inadequacy of the model or inaccuracy of the estimated model parameters. The SVPC can also be used to evaluate a covariate effect by plotting <italic>P<sub>i,j</sub></italic> versus any covariate of interest.</p>
<p>An R code for generating an SVPC can be found in Supplementary Document 1 and is also available upon request.</p>
</sec>
<sec id="section5-0091270010390040">
<title>Normalized Prediction Distribution Error</title>
<p>Computation of the npde has been described in detail by Brendel et al,<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref></sup> and a R package for computing an npde has been developed by Comets et al.<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> The npde is an improved version of pd by de-correlating multiple observations within the same participant. pd is the percentile of an observation in the marginal distribution of observations under H<sub>0</sub>,<sup><xref ref-type="bibr" rid="bibr10-0091270010390040">10</xref></sup> which is computed the same way as that of the SVPC. If a model describes the data well, npde should follow the standard normal distribution. For the npde computation, 1000 data sets were simulated using the final model based on the original data set by setting NSUBPROBLEMS = 1000 in NONMEM. The npde was performed using the R package for npde.<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup></p>
</sec>
<sec id="section6-0091270010390040">
<title>Simulation Studies</title>
<p>Simulation studies were conducted to compare the adequacy of the VPC and the SVPC in model evaluation and to demonstrate the applicability of the SVPC in various situations. In the simulation studies, observed data were simulated using predefined models (true models) with fixed and random effects. For simulation studies 1, 2, and 5, the observed data were then fitted by the true model and a false model. The false model could be either a wrong structure model or wrong parameter estimates. A VPC and an SVPC were created for the true and/or false models in each simulation study for the model(s) investigated.</p>
</sec>
</sec>
<sec id="section7-0091270010390040">
<title>Illustrative Examples</title>
<sec id="section8-0091270010390040">
<title>Phase 1 Case Study</title>
<p>Study A4991014 was a typical oncology first-in-patient dose escalation design for AG-014699, a potent inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1).<sup><xref ref-type="bibr" rid="bibr12-0091270010390040">12</xref></sup> In the study, a total of 32 patients with a mean body surface area (BSA) of 1.91 m<sup>2</sup> (BSA range, 1.32-2.44 m<sup>2</sup>) were enrolled, and 6 dose levels (1-18 mg/m<sup>2</sup>) of AG-014699 were tested. There were 3 to 6 patients in each dose group except the maximum tolerated dose (MTD) expansion cohort (12 mg/m<sup>2</sup>), which had 12 patients enrolled (<xref ref-type="table" rid="table1-0091270010390040">Table I</xref>). As in most early oncology studies, patients were dosed based on their BSA, and thus the total dose (mg dose) for each patient was different even for the patients enrolled in the same mg/m<sup>2</sup> dose group. Drug concentrations and PARP activity (a PD marker) were determined over time for each patient. To establish the relationship between drug concentration and its PARP inhibitory activity, a population PK/PD analysis was performed. The PK of AG-014699 was best described by a 3-compartment linear model, and the PD was best described by a simple E<sub>max</sub> model (unpublished work). Covariate analysis was performed, and BSA was found not to be a significant covariate on any PK or PD parameter (unpublished work).</p>
<table-wrap id="table1-0091270010390040" position="float">
<label>Table I</label>
<caption><p>Dose Groups of Study A4991014</p></caption>
<graphic alternate-form-of="table1-0091270010390040" xlink:href="10.1177_0091270010390040-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Dose Levels</th>
<th align="center">Dose, mg/m<sup>2</sup></th>
<th align="center">No. of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>6</td>
<td>18</td>
<td>6</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Since the purpose of this PK/PD modeling effort was to evaluate different dosing regimens when AG-014699 is given in combination with different chemotherapeutic agents, it is important to evaluate the predictive performance of the model. The VPC was used in the model validation steps. The VPC for the PK model was straightforward because although each patient received a different total dose of AG-014699 in mg, it could still be performed for all patients using dose-normalized PK data as a result of PK linearity. <xref ref-type="fig" rid="fig1-0091270010390040">Figure 1A</xref> shows the VPC of the PK model for 1 of 3 occasions where PK was evaluated.</p>
<fig id="fig1-0091270010390040" position="float">
<label>Figure 1.</label>
<caption><p>The visual predictive check (VPC) and standardized visual predictive check (SVPC) plots for AG-014699 pharmacokinetic (PK)/pharmacodynamic (PD) model evaluation. (A) VPC plot for AG-014699 PK model using dose (mg) normalized AG-014699 concentrations versus time. Open circles, actual observations; dashed line, 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data. (B, C) SVPC plots for AG-014699 PD model. Open circles, calculated P<sub>i,j</sub> for each observation versus time (B) and dose (C); dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted P<sub>i,j</sub> (from bottom to top).</p></caption>
<graphic xlink:href="10.1177_0091270010390040-fig1.tif"/>
</fig>
<p>However, a VPC for the PD model is a more complicated issue. A dose-normalized VPC as described above could not be performed because of the nonlinear nature of the PD model. A VPC stratified by dose groups was not a good option either as there were only 3 to 6 patients in most of the mg/m<sup>2</sup> dose groups even if we could ignore the difference in total mg dose within the same mg/m<sup>2</sup> dose group. Although the VPC is not applicable in this situation, the SVPC provides an alternative. As explained in the Methods section, the SVPC compares each individual’s observation at each time point to the 1000 model-simulated values corresponding to the same time point using the same design template of that individual. In this case, the same design template refers to the same dose and BSA. Thus, the <italic>P</italic><sub><italic>i,j</italic></sub> values obtained from this comparison are corrected for individual design features, such as dose and covariate values. These <italic>P</italic><sub><italic>i,j</italic></sub> values for all patients can then be presented on the same plot to evaluate model performance against time and/or other covariates of interest, regardless of the dose that each individual has taken. The result of the SVPC for the PD of AG-014699 versus time is shown in <xref ref-type="fig" rid="fig1-0091270010390040">Figure 1B</xref>. It is observed that the <italic>P</italic><sub><italic>i,j</italic></sub> values for the PD observations are in general uniformly distributed between 0 and 1 over time. Therefore, the PK/PD time course has been reasonably well defined by the PK/PD model with good predictive performance. The SVPC can also be used to evaluate covariate effects, as shown in <xref ref-type="fig" rid="fig1-0091270010390040">Figure 1C</xref>, in which the effect of dose on PD predictions is examined. Although an even distribution of <italic>P</italic><sub><italic>i,j</italic></sub> was observed at dose levels greater than 16 mg, there appeared to be a slight overestimation of PD effect at dose levels below 10 mg (subtherapeutic doses).</p>
</sec>
<sec id="section9-0091270010390040">
<title>Simulation Study 1: VPC Adequacy for Body Weight–Based Dosing</title>
<p>The PK data were simulated using a 1-compartment model. The true and false PD models are as follows:</p>
<p><disp-formula id="disp-formula4-0091270010390040">
<mml:math display="block" id="math7-0091270010390040">
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>True</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>PD</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>model</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mtext>E</mml:mtext>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>E</mml:mtext>
<mml:mrow>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mtext>Cp</mml:mtext>
<mml:mo stretchy="false">/</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mtext>EC</mml:mtext>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mtext>Cp</mml:mtext>
<mml:mo stretchy="false">)</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>False</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>PD</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>model</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:mtext>E</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>Slope</mml:mtext>
<mml:mo>⋅</mml:mo>
<mml:mtext>Cp</mml:mtext>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula4-0091270010390040" xlink:href="10.1177_0091270010390040-eq4.tif"/>
</disp-formula></p>
<p>where E<sub>max</sub> is the maximum PD effect (E), EC<sub>50</sub> is the concentration to achieve 50% of E<sub>max</sub>, and Cp is the concentration in plasma. The PK and PD parameters for the PK and PD models are shown in <xref ref-type="table" rid="table2-0091270010390040">Table II</xref>. Data for 100 patients were simulated with these patients receiving a body weight (BW)–based intravenous (IV) bolus dose (1.5 unit/kg) of a hypothetical drug. BW was not a covariate on any PK or PD parameter. The BW values were generated assuming a normal distribution with a mean of 70 kg and a range of 35.9 to 113.4 kg.</p>
<table-wrap id="table2-0091270010390040" position="float">
<label>Table II</label>
<caption>
<p>Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters for Simulation Study 1</p>
</caption>
<graphic alternate-form-of="table2-0091270010390040" xlink:href="10.1177_0091270010390040-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">Simulation</th>
<th align="center">True PD Model Estimates</th>
<th align="center">False PD Model Estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">PK</td>
</tr>
<tr>
<td> CL</td>
<td>0.5</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> V</td>
<td>1</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula4-0091270010390040">
<mml:math display="inline" id="math8-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>CL</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.04</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula5-0091270010390040">
<mml:math display="inline" id="math9-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mtext>V</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.04</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td> ε<sup>2</sup> (constant coefficient error)</td>
<td>0.01</td>
<td align="center">—</td>
<td align="center">—</td>
</tr>
<tr>
<td colspan="4">PD</td>
</tr>
<tr>
<td> E<sub>max</sub></td>
<td>200</td>
<td>188</td>
<td align="center">—</td>
</tr>
<tr>
<td> EC<sub>50</sub></td>
<td>70</td>
<td>68.8</td>
<td align="center">—</td>
</tr>
<tr>
<td> Slope</td>
<td align="center">—</td>
<td align="center">—</td>
<td>1.78</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula6-0091270010390040">
<mml:math display="inline" id="math10-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>Emax</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.09</td>
<td>0.0701</td>
<td align="center">—</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula7-0091270010390040">
<mml:math display="inline" id="math11-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>E</mml:mtext>
<mml:mn>50</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.04</td>
<td>0.0336</td>
<td align="center">—</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula8-0091270010390040">
<mml:math display="inline" id="math12-0091270010390040">
<mml:msubsup>
<mml:mtext>σ</mml:mtext>
<mml:mrow>
<mml:mi>Slope</mml:mi>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.119</td>
</tr>
<tr>
<td> ε<sup>2</sup> (constant coefficient error)</td>
<td>0.01</td>
<td>0.00981</td>
<td>0.125</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results of the VPC and the SVPC are presented in <xref ref-type="fig" rid="fig2-0091270010390040">Figure 2</xref>. In this case, both the VPC and the SVPC correctly identified misspecification in the false model, as shown in <xref ref-type="fig" rid="fig2-0091270010390040">Figures 2A</xref>,<xref ref-type="fig" rid="fig2-0091270010390040">C</xref>, respectively. However, the result of VPC would likely have rejected the true model because the 5th and 95th percentile intervals of model-simulated concentrations are wider than those of observed concentrations after the 2-hour sampling time point (<xref ref-type="fig" rid="fig2-0091270010390040">Figure 2B</xref>). On the other hand, SVPC was able to correctly identify the true model, as shown by the apparent uniform distribution of the <italic>P</italic><sub><italic>i,j</italic></sub> values between 0 and 1, and approximately 90% of <italic>P</italic><sub><italic>i,j</italic></sub> values were between 0.05 and 0.95 (<xref ref-type="fig" rid="fig2-0091270010390040">Figure 2D</xref>).</p>
<fig id="fig2-0091270010390040" position="float">
<label>Figure 2.</label>
<caption><p>The visual predictive check (VPC) and standardized visual predictive check (SVPC) plots of simulation study 1. (A, B) VPC and (C, D) SVPC plots for both false (A, C) and true (B, D) models were obtained as described in the Methods section. For A and B: open circles, actual observations; dashed line, 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data; dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of observed observations. For C and D: open circles, calculated P<sub>i,j</sub> for each observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted P<sub>i,j</sub> (from bottom to top); dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the calculated P<sub>i,j</sub> values for all the observations at each time point. Colors indicate patients with low (green), middle (black), and high (red) tertiles of body weight in all the plots. PD, pharmacodynamic.</p></caption>
<graphic xlink:href="10.1177_0091270010390040-fig2.tif"/>
</fig>
</sec>
<sec id="section10-0091270010390040">
<title>Simulation Study 2: VPC Adequacy When There Is a Covariate Effect on PK or PD Parameters</title>
<p>The PK data were simulated using a 1-compartment model with BW as a covariate on clearance <inline-formula id="inline-formula9-0091270010390040">
<mml:math display="inline" id="math13-0091270010390040">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>CL</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>TVCL</mml:mtext>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>BW</mml:mtext>
<mml:mo stretchy="false">/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>BW</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>median</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mi>α</mml:mi>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>. The correct and incorrect estimates of intersubject variability are as follows:</p>
<p><disp-formula id="disp-formula5-0091270010390040">
<mml:math display="block" id="math14-0091270010390040">
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mtext>Correct</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>estimate</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>CL</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>10</mml:mn>
<mml:mi>%</mml:mi>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mtext>Incorrect</mml:mtext>
<mml:mspace width="0.25em"/>
<mml:mtext>estimate</mml:mtext>
<mml:mo>:</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>CL</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>25</mml:mn>
<mml:mi>%</mml:mi>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula5-0091270010390040" xlink:href="10.1177_0091270010390040-eq5.tif"/>
</disp-formula></p>
<p>The parameters for the PK model are shown in <xref ref-type="table" rid="table3-0091270010390040">Table III</xref>. Data were simulated for 100 participants, and all the participants received a fixed dose (100 units) of a hypothetical drug. The BW values were generated assuming a normal distribution with a mean of 70 kg and a range of 30.5 to 125 kg.</p>
<table-wrap id="table3-0091270010390040" position="float">
<label>Table III</label>
<caption>
<p>Pharmacokinetic Parameters for Simulation Study 2</p>
</caption>
<graphic alternate-form-of="table3-0091270010390040" xlink:href="10.1177_0091270010390040-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">Simulation</th>
<th align="center">Correct Parameter Estimates</th>
<th align="center">Specified Incorrect Estimates</th>
</tr>
</thead>
<tbody>
<tr>
<td>TVCL</td>
<td>0.3</td>
<td>0.297</td>
<td>0.297</td>
</tr>
<tr>
<td>α</td>
<td>0.75</td>
<td>0.737</td>
<td>0.737</td>
</tr>
<tr>
<td>V</td>
<td>1</td>
<td>1.01</td>
<td>1.01</td>
</tr>
<tr>
<td><inline-formula id="inline-formula10-0091270010390040">
<mml:math display="inline" id="math15-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>CL</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.01</td>
<td>0.00839</td>
<td>0.0625</td>
</tr>
<tr>
<td><inline-formula id="inline-formula11-0091270010390040">
<mml:math display="inline" id="math16-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mtext>V</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.04</td>
<td>0.0467</td>
<td>0.0467</td>
</tr>
<tr>
<td>ε<sup>2</sup> (constant coefficient error)</td>
<td>0.01</td>
<td>0.00989</td>
<td>0.00989</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The results of the VPC and the SVPC are shown in <xref ref-type="fig" rid="fig3-0091270010390040">Figures 3A</xref>-<xref ref-type="fig" rid="fig3-0091270010390040">D</xref>. For the VPC, it is difficult to differentiate the model with the incorrect estimate (<xref ref-type="fig" rid="fig3-0091270010390040">Figure 3A</xref>), which had more than 150% overestimation of the intersubject variability on CL, from that with the correct estimate (<xref ref-type="fig" rid="fig3-0091270010390040">Figure 3B</xref>). Conversely, the SVPC was able to clearly separate the 2 estimates, as shown in <xref ref-type="fig" rid="fig3-0091270010390040">Figure 3D</xref> (correct estimate) and <xref ref-type="fig" rid="fig3-0091270010390040">Figure 3C</xref> (incorrect estimate), with a reasonable number of the <italic>P</italic><sub><italic>i,j</italic></sub> values below the 5th and above the 95th percentiles for the correct estimate and almost all <italic>P</italic><sub><italic>i,j</italic></sub> values between the 5th and 95th percentiles after the 2-hour sampling time point for the incorrect estimate.</p>
<fig id="fig3-0091270010390040" position="float">
<label>Figure 3.</label>
<caption>
<p>The visual predictive check (VPC) and standardized visual predictive check (SVPC) plots of simulation study 2. (A, B) VPC and (C, D) SVPC plots for both incorrect (A, C) and correct (B, D) parameter estimates were obtained as described in the Methods section. For A and B: open circles, actual observations; dashed line, 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data; dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the actual observations. For C and D: open circles, calculated P<sub>i,j</sub> value for each observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted P<sub>i,j</sub> (from bottom to top); dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the calculated P<sub>i,j</sub> values of all the observations at each time point. Colors indicate patients with low (green), middle (black), and high (red) tertiles of body weight in all the plots. PK, pharmacokinetics.</p>
</caption>
<graphic xlink:href="10.1177_0091270010390040-fig3.tif"/>
</fig>
</sec>
<sec id="section11-0091270010390040">
<title>Simulation Study 3: Application of SVPC for Different Study Designs, Including Adaptive Design</title>
<p>The PK data were simulated using a 1-compartment model. A hypothetical drug was dosed by 1-hour IV infusion. Five patients received a daily dose (qd), and 19 patients received a twice-daily dose (bid). The VPC results are shown in <xref ref-type="fig" rid="fig4-0091270010390040">Figures 4A</xref>,<xref ref-type="fig" rid="fig4-0091270010390040">B</xref> for the VPC and <xref ref-type="fig" rid="fig4-0091270010390040">Figure 4C</xref> for the SVPC. Because of the difference in dosing schedule, the VPC has to be performed separately for each dosing schedule. For the qd schedule, which has only 5 patients, the distribution cannot be meaningfully evaluated. However, a single SVPC can be performed, including all patients regardless of their dosing schedule, as shown in <xref ref-type="fig" rid="fig4-0091270010390040">Figure 4C</xref>. In addition, when the overall time period of the observations is too long and compresses earlier time points in a plot (<xref ref-type="fig" rid="fig4-0091270010390040">Figure 4C</xref>), we may simply plot <italic>P</italic><sub><italic>i,j</italic></sub> versus time after the last dose to obtain a clearer graphical presentation (<xref ref-type="fig" rid="fig4-0091270010390040">Figure 4D</xref>) if desired.</p>
<fig id="fig4-0091270010390040" position="float">
<label>Figure 4.</label>
<caption>
<p>The visual predictive check (VPC) and standardized visual predictive check (SVPC) plots of simulation study 3. (A, B) VPC and (C, D) SVPC plots for qd (A), bid (B), and combined (C, D) data sets were obtained as described in the Methods section. For A and B: open circles, actual observations; dashed line, 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data. For C and D: open circles, calculated P<sub>i,j</sub> value for each observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted P<sub>i,j</sub> (from bottom to top). C: P<sub>i,j</sub> versus time after the first dose; D: P<sub>i,j</sub> versus time after the most recent dose.</p>
</caption>
<graphic xlink:href="10.1177_0091270010390040-fig4.tif"/>
</fig>
</sec>
<sec id="section12-0091270010390040">
<title>Simulation Study 4: Evaluation of Covariate Effect(s) Using SVPC</title>
<sec id="section13-0091270010390040">
<title>Example 1</title>
<p>PK data were simulated using a 1-compartment model with first-order absorption and BW as a covariate on clearance <inline-formula id="inline-formula12-0091270010390040">
<mml:math display="inline" id="math17-0091270010390040">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>CL</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>TVCL</mml:mtext>
<mml:msubsup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>BW</mml:mtext>
<mml:mo stretchy="false">/</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>BW</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>median</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mtext>BW</mml:mtext>
</mml:mrow>
<mml:mi>α</mml:mi>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>. Data were simulated for 100 participants with a normal distribution of BW (median, 70 kg; range, 30.5-120 kg). The results of the SVPC are shown in <xref ref-type="fig" rid="fig5-0091270010390040">Figures 5A</xref>,<xref ref-type="fig" rid="fig5-0091270010390040">B</xref> for the base model (without covariate) and final model (with BW as a covariate), respectively. The BW effect on the concentration-time course was evaluated by grouping participants into tertiles of low (green), middle (black), and high (red) BW to identify the parameter on which BW has an effect. In the SVPC plot for the base model (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5A</xref>), when time increases, concentrations of the patients with high body weight are overestimated, with most of the red symbols below the 50th percentile on the SVPC plot, and it is the opposite for low BW patients, with most of the green symbols above the 50th percentile. In the SVPC plot for the final model with BW as a covariate on CL (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5B</xref>), this color separation disappears.</p>
<fig id="fig5-0091270010390040" position="float">
<label>Figure 5.</label>
<caption>
<p>The standardized visual predictive check (SVPC) plots for simulation study 4. SVPC plots for the (A, C) base and (B, D) full models in 2 scenarios were obtained as described in Methods. These 2 scenarios are (1) body weight (BW) is a covariate on CL (A, B), and (2) AGE is a covariate on absorption rate k<sub>a</sub> (C, D). Open circles, calculated P<sub>i,j</sub> for each observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted P<sub>i,j</sub> (from bottom to top). Colors indicate patients with low (green), middle (black), and high (red) tertiles of BW for A and B, as well as low (green), middle (black), and high (red) tertiles of AGE for C and D.</p>
</caption>
<graphic xlink:href="10.1177_0091270010390040-fig5.tif"/>
</fig>
</sec>
<sec id="section14-0091270010390040">
<title>Example 2</title>
<p>The PK data were simulated using a 1-compartment model with first-order absorption. Age is a covariate for the absorption rate constant <inline-formula id="inline-formula13-0091270010390040">
<mml:math display="inline" id="math18-0091270010390040">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>a</mml:mtext>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mtext>TVKA</mml:mtext>
<mml:msup>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>AGE</mml:mtext>
<mml:mo>\</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mtext>AGE</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>median</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mi>α</mml:mi>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula>. Data were simulated for 100 patients with a uniform distribution for age (median, 40 years; range, 18.6-64.7 years). The results of the SVPC are shown in <xref ref-type="fig" rid="fig5-0091270010390040">Figures 5C</xref>,<xref ref-type="fig" rid="fig5-0091270010390040">D</xref> for the base model (without covariate) and full model (with age as covariate on k<sub>a</sub>), respectively. The age effect on the concentration-time course was evaluated by grouping participants into tertiles of low (green), middle (black), and high (red) values of age to identify the parameter on which age has an effect. As compared to example 1 (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5A</xref>), the color separation in the SVPC plot occurred at early time points for the base model (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5C</xref>) and is less apparent at later time points. In the SVPC plot for the final model with age as a covariate on k<sub>a</sub>, the colors are evenly distributed between 0 and 1 (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5D</xref>).</p>
</sec>
</sec>
<sec id="section15-0091270010390040">
<title>Simulation Study 5: Comparison of SVPC vs npde</title>
<p>In this simulation study, we used the PK/PD model similar to that of warfarin<sup><xref ref-type="bibr" rid="bibr11-0091270010390040">11</xref>,<xref ref-type="bibr" rid="bibr13-0091270010390040">13</xref>,<xref ref-type="bibr" rid="bibr14-0091270010390040">14</xref></sup> but eliminated the BW covariate effect term in the warfarin model because the focus was to evaluate the ability of the SVPC and the npde to detect a false structure model. The drug plasma concentration was described by a 1-compartment model with first-order absorption:</p>
<p><disp-formula id="disp-formula6-0091270010390040">
<mml:math display="block" id="math19-0091270010390040">
<mml:mrow>
<mml:mtext>C</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mtext>F</mml:mtext>
<mml:mo>⋅</mml:mo>
<mml:mtext>D</mml:mtext>
<mml:mo>⋅</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>a</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mtext>V</mml:mtext>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>a</mml:mtext>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>e</mml:mtext>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>×</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mtext>e</mml:mtext>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>a</mml:mtext>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>t</mml:mtext>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>t</mml:mtext>
<mml:mrow>
<mml:mtext>lag</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mtext>e</mml:mtext>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mtext>a</mml:mtext>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>t</mml:mtext>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>t</mml:mtext>
<mml:mrow>
<mml:mtext>lag</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-0091270010390040" xlink:href="10.1177_0091270010390040-eq6.tif"/>
</disp-formula></p>
<p>where F is bioavailability and was assumed to be 100%, and D is the dose. k<sub>a</sub> and k<sub>e</sub> are the first-order absorption and elimination rate constants, respectively. V is the volume of distribution, and t<sub>lag</sub> is the absorption lag time.</p>
<p>The PD endpoint was described by an indirect response model driven by drug plasma concentration Cp. The PK and PD data were simulated for 70 participants and then fitted using the true PD model and a false model. The PK/PD parameters are shown in <xref ref-type="table" rid="table4-0091270010390040">Table IV</xref>.</p>
<table-wrap id="table4-0091270010390040" position="float">
<label>Table IV</label>
<caption>
<p>Pharmacokinetic (PK)/Pharmacodynamic (PD) Parameters for Simulation Study 5</p>
</caption>
<graphic alternate-form-of="table4-0091270010390040" xlink:href="10.1177_0091270010390040-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parameters</th>
<th align="center">Simulation</th>
<th align="center">Parameter Estimates From the True Model</th>
<th align="center">Parameter Estimates From the False Model</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">PK</td>
</tr>
<tr>
<td> CL</td>
<td>0.1</td>
<td>0.0993</td>
<td>0.993</td>
</tr>
<tr>
<td> V</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td> Tabs<sub>1/2</sub></td>
<td>0.5</td>
<td>0.889</td>
<td>0.889</td>
</tr>
<tr>
<td> t<sub>lag</sub></td>
<td>0.8</td>
<td>0.593</td>
<td>0.584</td>
</tr>
<tr>
<td> Teo<sub>1/2</sub></td>
<td>—</td>
<td>—</td>
<td>25.8</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula14-0091270010390040">
<mml:math display="inline" id="math20-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>CL</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.09</td>
<td>0.0578</td>
<td>0.0601</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula15-0091270010390040">
<mml:math display="inline" id="math21-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mtext>V</mml:mtext>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.01</td>
<td>0.0107</td>
<td>0.00981</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula16-0091270010390040">
<mml:math display="inline" id="math22-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>Tabs</mml:mtext>
<mml:mn>1/2</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.6</td>
<td>0.517</td>
<td>0.529</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula17-0091270010390040">
<mml:math display="inline" id="math23-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>tlag</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.5</td>
<td>0.789</td>
<td>0.828</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula18-0091270010390040">
<mml:math display="inline" id="math24-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>Teo</mml:mtext>
<mml:mn>1/2</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>—</td>
<td>—</td>
<td>0.0621</td>
</tr>
<tr>
<td> ε1<sup>2</sup></td>
<td>0.01</td>
<td>0.000619</td>
<td>0.000939</td>
</tr>
<tr>
<td> ε2<sup>2</sup></td>
<td>0.09</td>
<td>0.831</td>
<td>0.818</td>
</tr>
<tr>
<td colspan="4">PD</td>
</tr>
<tr>
<td> E<sub>max</sub></td>
<td>1</td>
<td>1 (fixed)</td>
<td>277</td>
</tr>
<tr>
<td> EC<sub>50</sub></td>
<td>1.5</td>
<td>1.7</td>
<td>4.42</td>
</tr>
<tr>
<td> E<sub>0</sub></td>
<td>200</td>
<td>202</td>
<td>202</td>
</tr>
<tr>
<td> Tout<sub>1/2</sub></td>
<td>10</td>
<td>10.5</td>
<td>—</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula19-0091270010390040">
<mml:math display="inline" id="math25-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>Emax</mml:mtext>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0 (fixed)</td>
<td>0 (fixed)</td>
<td>0 (fixed)</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula20-0091270010390040">
<mml:math display="inline" id="math26-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>E</mml:mtext>
<mml:mn>50</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.2</td>
<td>0.208</td>
<td>0.101</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula21-0091270010390040">
<mml:math display="inline" id="math27-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>E</mml:mtext>
<mml:mn>0</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.01</td>
<td>0.0131</td>
<td>0.0114</td>
</tr>
<tr>
<td> <inline-formula id="inline-formula22-0091270010390040">
<mml:math display="inline" id="math28-0091270010390040">
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mtext>Tout</mml:mtext>
<mml:mn>1/2</mml:mn>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:math>
</inline-formula></td>
<td>0.04</td>
<td>0.0352</td>
<td>—</td>
</tr>
<tr>
<td> ε<sup>2</sup></td>
<td>30</td>
<td>32.3</td>
<td>43.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010390040">
<p>CL = ke · V, Tabs<sub>1/2</sub> = 0.693/k<sub>a</sub>, Teo<sub>1/2</sub> = 0.693/keo, Tout<sub>1/2</sub> = 0.693/k<sub>out</sub>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>True PD model:</p>
<p><disp-formula id="disp-formula7-0091270010390040">
<mml:math display="block" id="math29-0091270010390040">
<mml:mtable columnalign="left">
<mml:mtr>
<mml:mtd>
<mml:mfrac>
<mml:mrow>
<mml:mtext>dP</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>dt</mml:mtext>
</mml:mrow>
</mml:mfrac>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>in</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mtext>E</mml:mtext>
<mml:mrow>
<mml:mtext>max</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mtext>Cp</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>EC</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mtext>Cp</mml:mtext>
</mml:mrow>
</mml:mfrac>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>out</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mtext>P</mml:mtext>
<mml:mo>,</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>in</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mtext>k</mml:mtext>
<mml:mrow>
<mml:mtext>out</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mtext>P</mml:mtext>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula7-0091270010390040" xlink:href="10.1177_0091270010390040-eq7.tif"/>
</disp-formula></p>
<p>where k<sub>in</sub> represents the zero-order production rate of the PD endpoint without drug effect, and k<sub>out</sub> represents the first-order degradation rate of the PD endpoint. P and P0 represent PD values at time t and baseline, respectively. E<sub>max</sub> and EC<sub>50</sub> represent the maximal drug effect and the drug plasma concentration required to achieve 50% of E<sub>max</sub>, respectively.</p>
<p>False PD model:</p>
<p><disp-formula id="disp-formula8-0091270010390040">
<mml:math display="block" id="math30-0091270010390040">
<mml:mrow>
<mml:mtext>P</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>P</mml:mtext>
<mml:mn>0</mml:mn>
<mml:mo>−</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mtext>E</mml:mtext>
<mml:mrow>
<mml:mi>max</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mtext>Ce</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mtext>EC</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mtext>Ce</mml:mtext>
</mml:mrow>
</mml:mfrac>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-0091270010390040" xlink:href="10.1177_0091270010390040-eq8.tif"/>
</disp-formula></p>
<p>where Ce is the drug concentration at the effect site.</p>
<p>Typical VPC, SVPC, and npde analyses were conducted for the false model, the fitted true model (model with parameters estimated by fitting the original data set using the true model), and the original true model (model used for simulation of the original data set). The statistical output for npde is shown in <xref ref-type="table" rid="table5-0091270010390040">Table V</xref> for both the true and false models. As expected, the VPC was able to detect the false model (<xref ref-type="fig" rid="fig6-0091270010390040">Figure 6A</xref>). However, although the SVPC can clearly identify the false model (<xref ref-type="fig" rid="fig6-0091270010390040">Figure 6G</xref>) with observed 90th percentiles consistently narrower than the model-predicted ones between 20 and 80 hours after dose, this trend is not observed in the npde plot (<xref ref-type="fig" rid="fig6-0091270010390040">Figure 6D</xref>), nor do the statistical tests reject the false model (<xref ref-type="table" rid="table5-0091270010390040">Table V</xref>) by the npde approach. When the simulated data (as observed data) were fitted with the true PK and PD models, some of the PK parameter estimates (ie, Tabs<sub>1/2</sub> and t<sub>lag</sub>) were not well estimated because of the lack of data in the absorption phase (<xref ref-type="table" rid="table4-0091270010390040">Table IV</xref>). This is reflected in both the VPC and SVPC plots (<xref ref-type="fig" rid="fig6-0091270010390040">Figures 6B</xref>,<xref ref-type="fig" rid="fig6-0091270010390040">H</xref>) with a more apparent separation between the observed and model-predicted 50th percentiles in the SVPC plot. This benefit comes from normalizing observations to a standard percentile scale and transformation of a normal distribution (VPC) to a uniform distribution (SVPC). By displaying all observations on the same scale across time points, the deviation at each time point can be presented with equal clarity. This is especially important when the observed values cover a large range or multiple logs.</p>
<table-wrap id="table5-0091270010390040" position="float">
<label>Table V</label>
<caption>
<p>Statistical Output of Normalized Prediction Distribution Error (npde) Using the R Package</p>
</caption>
<graphic alternate-form-of="table5-0091270010390040" xlink:href="10.1177_0091270010390040-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">False Model</th>
<th align="center">True Model (Original Parameters)</th>
<th align="center">True Model (Parameters Obtained From Fitting)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Distribution of npde</td>
</tr>
<tr>
<td> Mean</td>
<td>−0.09199</td>
<td>−0.01391</td>
<td>−0.0578</td>
</tr>
<tr>
<td> Variance</td>
<td>0.9624</td>
<td>1.061</td>
<td>0.9967</td>
</tr>
<tr>
<td> Skewness</td>
<td>0.01764</td>
<td>−0.01070</td>
<td>0.03246</td>
</tr>
<tr>
<td> Kurtosis</td>
<td>−0.1378</td>
<td>−0.1734</td>
<td>−0.2036</td>
</tr>
<tr>
<td colspan="4">Statistical tests</td>
</tr>
<tr>
<td> Wilcoxon signed rank test</td>
<td>0.0336</td>
<td>0.811</td>
<td>0.168</td>
</tr>
<tr>
<td> Fisher variance test</td>
<td>0.537</td>
<td>0.31</td>
<td>0.972</td>
</tr>
<tr>
<td> Shapiro-Wilk test of normality</td>
<td>0.866</td>
<td>0.487</td>
<td>0.827</td>
</tr>
<tr>
<td> Global adjusted <italic>P</italic> value</td>
<td>0.101</td>
<td>0.93</td>
<td>0.505</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig6-0091270010390040" position="float">
<label>Figure 6.</label>
<caption>
<p>The visual predictive check (VPC), normalized prediction distribution error (npde), and standardized visual predictive check (SVPC) plots of simulation study 5. (A-C) VPC, (D-F) npde, and (G-I) SVPC plots for the false model (A, D, G), the true model with parameters obtained from fitting (B, E, H) and the true model with original parameters (C, F, I) were obtained as described in the Methods section. For A-C: open circles, actual observations; dashed line, 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data; dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the actual observations. For D-F: open circles, calculated npde for each actual observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of npde (from bottom to top); dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the calculated npde of all the observations at each time point. For G-I: open circles, calculated <italic>P</italic><sub><italic>i,j</italic></sub> for each observation; dashed line, model-predicted 5th, 50th, and 95th percentiles of model-predicted <italic>P</italic><sub><italic>i,j</italic></sub> (from bottom to top); dotted line, 5th, 50th, and 95th percentiles (from bottom to top) of the calculated <italic>P</italic><sub><italic>i,j</italic></sub> of all the observations at each time point.</p>
</caption>
<graphic xlink:href="10.1177_0091270010390040-fig6.tif"/>
</fig>
<p>When the original true model was used to conduct the VPC, SVPC, and npde analyses, the observed percentiles overlay very well with the model-predicted percentiles for all 3 approaches (<xref ref-type="fig" rid="fig6-0091270010390040">Figures 6C</xref>,<xref ref-type="fig" rid="fig6-0091270010390040">F</xref>,<xref ref-type="fig" rid="fig6-0091270010390040">I</xref>).</p>
</sec>
</sec>
<sec id="section16-0091270010390040">
<title>Discussion</title>
<p>The VPC is a commonly used tool for model evaluation. It provides a visual inspection of whether the model can resemble the data from which it was derived by comparing the distribution of the observed data to the distribution of the model-simulated data.<sup><xref ref-type="bibr" rid="bibr6-0091270010390040">6</xref>,<xref ref-type="bibr" rid="bibr11-0091270010390040">11</xref></sup> Generally speaking, the comparison between the 50th percentiles (50th percentile of observed data vs 50th percentile of model-predicted data) gives us information mainly about the structure model, whereas the comparison of the 5th and 95th percentiles (used as an example in this study, but other percentiles of interest can be used) mainly shows whether the random effects are adequately determined. There are situations when 2 (or more) structural models are not distinguishable based on the 50th percentile comparison, whereas 5th and 95th percentile comparisons may show one model describes the data better than the other, as shown in simulation study 5. In this example, the typical PD profiles generated from the false model (link model) and the true model (indirect model) overlaid on top of each other (data not shown), indicating that data did not support identification of the true model based on typical PD profiles. However, parameterizations of random effects on different PD models revealed the difference between the 2 models.</p>
<p>A VPC could not be meaningfully performed for the PD model of the phase 1 case study because each patient had taken a different dose (in mg), and the PD model was nonlinear. The 5th and 95th percentiles in the VPC plot in this case would have been mainly determined by the patients in the lowest and highest dose cohorts, respectively. Patients in cohorts with doses between the low and high doses would contribute little to the evaluation of random effects. This led us to develop an alternative approach to complement the typical VPC. With the objective of eliminating fixed effect (dose in this case) at each observation time point, we conducted a VPC on a standardized scale (SVPC) by comparing each observation to its corresponding 1000 simulated concentrations based on the same design template. Therefore, this comparison is between the observed and simulated concentrations at the same time point and for the same subject, factoring out patient-specific characteristics (dose in this case).</p>
<sec id="section17-0091270010390040">
<title>Inadequacy of Typical VPC When the Final Model Contains a Continuous Covariate</title>
<p>Having worked through the issues encountered in the phase 1 case scenario, we started to question whether there were other situations where the VPC may not be appropriate and where the SVPC should be used instead. The VPC has been generally applied for the final/full model regardless of the presence of covariate effect(s) in many reported population PK/PD studies. To evaluate whether this is a good practice, we conducted a set of simulation studies for selected scenarios. For illustration purposes, extreme situations were used in these examples.</p>
<p>In simulation study 1, patients received BW-based dosing, whereas BW was not a covariate on any PK or PD parameter. As shown in <xref ref-type="fig" rid="fig2-0091270010390040">Figure 2B</xref>, the VPC failed to identify the correct model. The random effects seem to be overestimated. By grouping patients into low, middle, and high BW tertiles by color, the VPC clearly showed that the 5th and 95th percentiles reflect not only the random effects but also the fixed effects, as indicated in red at the top and in green at the bottom (<xref ref-type="fig" rid="fig2-0091270010390040">Figure 2B</xref>). The 5th percentile of simulated concentration was determined mainly by patients with low BW, whereas the 95th percentile was determined mainly by patients with high body weight. For patients whose BW fell into the middle tertile, their concentrations could rarely fall outside of the 90th percentile interval if the random effects were less than the sum of fixed and random effects of patients with extreme BW, even when they have high η values (intersubject variability). This could cause rejection of a true model. To adequately evaluate the random effects, participants in each tertile should contribute equally to the 90th percentile interval determination.</p>
<p>Simulation study 2 presented a situation in which patients received a fixed dose, whereas BW was a covariate on CL. This is a common situation in drug development. As shown in <xref ref-type="fig" rid="fig3-0091270010390040">Figures 3A</xref>,<xref ref-type="fig" rid="fig3-0091270010390040">B</xref>, the VPC could not effectively differentiate the wrong intersubject variability estimate for CL from the correct estimate. By mixing fixed and random effects, the ability of the VPC in detecting the inadequacy of the random effects was reduced. Although BW effect on CL was used as an example here, the same conclusion applies to any covariate effects in a final model.</p>
<p>How should a VPC be used when there is an influential covariate(s) on PK/PD parameters?</p>
<sec id="section18-0091270010390040">
<title>Single categorical covariate</title>
<p>When an influential covariate is a categorical variable, such as gender, a VPC may be performed by stratifying the data set by this covariate if there are enough participants in each category to evaluate the distribution.</p>
</sec>
<sec id="section19-0091270010390040">
<title>Multiple categorical covariates</title>
<p>When there are multiple covariates in the final model, multiple strata are needed to remove the fixed effects in a VPC presentation. As the number of strata increases, the number of participants decreases in each VPC plot, and so does the power of detecting model misspecification. These plots become meaningless when the number of participants in each category becomes too small.</p>
</sec>
<sec id="section20-0091270010390040">
<title>Continuous covariates</title>
<p>When influential covariates are continuous variables, stratification is difficult or arbitrary. In this case, the VPC has little utility and could be misleading.</p>
</sec>
</sec>
<sec id="section21-0091270010390040">
<title>Applications of SVPC</title>
<sec id="section22-0091270010390040">
<title>Final Model Includes Covariate Effect(s)</title>
<p>When a VPC is not appropriate in the situations such as those discussed above, the SVPC can be performed. Regardless of the type and number of covariates contained in the final model, the distribution of observations in relation to model-simulated values (<italic>P</italic><sub><italic>i,j</italic></sub>) can be presented on a single plot for the entire population used in the analysis. As illustrated in simulation studies 1 and 2, where either an individualized dose was given (simulation study 1) or there is a continuous covariate in the final model (BW; simulation study 2), the SVPC was successful in identifying the right model and the wrong model. This was achieved by removing the fixed effects from the VPC plots. It shows that the tertile-related colors are evenly distributed between 0 and 1, indicating that patients with different BW contributed equally to the percentile determination, and the percentiles (except for the 50th percentile) reflect only random effects.</p>
</sec>
<sec id="section23-0091270010390040">
<title>Variation Among Patients During Study Conduct and Study Design, Including Adaptive Design</title>
<p>The key of the SVPC approach is that it removes the fixed effects from the visual display. This leads to its numerous applications, including addressing design differences between individuals and variations in study conduct.</p>
<p>During drug development, there are often situations when study design changes during the study and among participants. As presented in simulation study 3, a first-in-human study was designed with once-daily dosing (qd) based on the half-life predicted from the preclinical model. However, the PK data from first cohort showed that the half-life was shorter than expected. So from the second cohort on, the dosing interval was switched to twice-daily dosing (bid). To conduct the VPC correctly, one had to create a VPC plot separately for each dosing schedule (<xref ref-type="fig" rid="fig4-0091270010390040">Figures 4A</xref>,<xref ref-type="fig" rid="fig4-0091270010390040">B</xref>). As observed in <xref ref-type="fig" rid="fig4-0091270010390040">Figure 4A</xref>, the distribution of observed concentrations could not be adequately evaluated because there were only very few patients in the qd schedule. However, by performing an SVPC, the <italic>P</italic><sub><italic>i,j</italic></sub> values from all participants can be plotted on the same graph regardless of their schedule as each observation was compared to the simulated concentrations based on each participant’s own design (<xref ref-type="fig" rid="fig4-0091270010390040">Figure 4C</xref>).</p>
<p>When an adaptive design is used for the study, the SVPC can be performed by using the actual dosing record for each participant.</p>
</sec>
<sec id="section24-0091270010390040">
<title>Combining Data Following Each Dose</title>
<p>When the observation time period is long (simulation study 3), one can plot <italic>P</italic><sub><italic>i,j</italic></sub> versus time after the last dose, instead of versus time after the first dose, to obtain a clearer graphical presentation (<xref ref-type="fig" rid="fig4-0091270010390040">Figure 4D</xref>) if desired. This approach works for the SVPC whether the observation is after the first dose, at steady state, or in between. It is also valid when there is an accumulation after multiple dosing as all the dose effect has been removed from the visual display in the SVPC.</p>
</sec>
<sec id="section25-0091270010390040">
<title>Covariate Evaluation and Identification</title>
<p>As seen in the phase 1 case study, the SVPC can be used to evaluate a covariate effect by plotting <italic>P</italic><sub><italic>i,j</italic></sub> versus the covariates of interest (<xref ref-type="fig" rid="fig1-0091270010390040">Figure 1C</xref>). Another application is to identify potential covariates by plotting the <italic>P</italic><sub><italic>i,j</italic></sub> versus time. The advantage of this plot is that by grouping patients into different colors based on the covariate of interest, we can get some information on which parameter this potential covariate may have an effect.</p>
<p><xref ref-type="fig" rid="fig5-0091270010390040">Figure 5A</xref> shows the SVPC for the base model grouped by BW. It shows that when time increases, concentrations of patients with high body weight are overestimated, with most of the green points below average, and is the opposite for the patients with low BW. These observations provide information regarding the PK parameter(s) that BW may have an effect on. In this case, CL is a good candidate as it has no influence on concentration at time 0, but the effect increases over time. <xref ref-type="fig" rid="fig5-0091270010390040">Figure 5B</xref> is the SVPC based on the full model with BW as a covariate on CL and shows that the color trend disappears.</p>
<p><xref ref-type="fig" rid="fig5-0091270010390040">Figure 5C</xref> shows the SVPC for the base model of another drug grouped by AGE. There is a tertile-related color separation at the absorption phase. When AGE is included as a covariate on k<sub>a</sub>, the color trend disappears (<xref ref-type="fig" rid="fig5-0091270010390040">Figure 5D</xref>).</p>
</sec>
<sec id="section26-0091270010390040">
<title>SVPC vs npde</title>
<p>Although developed independently, the calculation of <italic>P</italic><sub><italic>i,j</italic></sub> in the SVPC is the same as the prediction discrepancy (pd) analysis proposed by Mentré and Escolano<sup><xref ref-type="bibr" rid="bibr10-0091270010390040">10</xref></sup> for a different model validation approach. The pd approach was intended to provide a global test of consistency of the entire data with the assumed model rather than for the purpose of a visual predictive check along the time course. It is based on the idea that if the model is true, then the raw residuals across all time points can be combined and be appropriately “standardized” (ie, to a set of values between 0 and 1 with uniform distribution). As the test is based on pooled data across time points from each participant, a de-correlation of multiple observations within each participant is needed to prevent type I error inflation. Therefore, Brendel et al<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref></sup> and Comets et al<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> later proposed an improved version in which the uncorrelated version of pd was transformed to a set of independent values following a normal distribution with mean 0 and variance 1, which was termed normalized prediction distribution errors (npde).</p>
<p>However, de-correlation comes with the cost of increasing the type II error (ie, the sensitivity of detecting misfits) when residuals are plotted against covariates. For example, when time is a covariate and the structural model is misspecified, one expects to see a trend as a function of time—which is the purpose of plotting against time. Unfortunately, the natural time trend expected in the raw residuals is not necessarily preserved by the de-correlation, and thus the ability to graphically detect model misspecification is reduced. This can be seen from the SVPC and npde plots of simulation study 5 (<xref ref-type="fig" rid="fig6-0091270010390040">Figure 6</xref>), in which the performance of the SVPC and npde on evaluating the PK/PD model of a hypothetical drug was compared. Although the SVPC was able to detect the model misspecification, both the npde plot and statistical test failed to identify the wrong model. Although the plot of npde versus time has been included in the evaluation graphs in the study and the R package for npde by Brendel et al<sup><xref ref-type="bibr" rid="bibr8-0091270010390040">8</xref></sup> and Comets et al,<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> it was not intended to evaluate the time dependency of the discrepancy between data and model. Similar problems exist if the npde is plotted against covariates other than time (eg, dose group, treatment, or weight). Therefore, since the main purpose of a visual predictive check is to suggest evidence of potential misspecification by evaluating the distribution of raw residuals as a function of time or other covariates, it is better performed without de-correlation because there are no repeated measurements at each time point or covariate values from each individual.</p>
<p>Although the calculation of <italic>P</italic><sub><italic>i,j</italic></sub> is the same as pd proposed by Mentré and Escolano,<sup><xref ref-type="bibr" rid="bibr10-0091270010390040">10</xref></sup> the SVPC approach was developed in the context of the visual predictive check. Therefore, this method was named SVPC since pd was intended for a different model validation approach. The SVPC may be viewed as an extended application of pd or a variation of npde.</p>
</sec>
<sec id="section27-0091270010390040">
<title>Number of Simulations Needed for SVPC</title>
<p>In this article, we set NSUBPROBLEMS = 1000 in NONMEM as the number of participants in each example was no more than 100. A higher NSUBPROBLEMS value might be necessary, as discussed by Comets et al,<sup><xref ref-type="bibr" rid="bibr9-0091270010390040">9</xref></sup> when the number of participants increases in the analysis.</p>
</sec>
</sec>
<sec id="section28-0091270010390040">
<title>Limitations of SVPC</title>
<p>Although the SVPC is generally robust, there are some limitations. By normalizing the observations to a standard scale, we lose the shape of the PK/PD time profile as well as the information regarding the absolute magnitude of PK/PD measurements. Although this is not critical in terms of model evaluation, it does introduce inconvenience in presenting the changes of PK and PD endpoint versus time. The prediction-corrected visual predictive check (PC-VPC) proposed by Bergstrand et al<sup><xref ref-type="bibr" rid="bibr15-0091270010390040">15</xref></sup> partially addresses this issue but has its own drawbacks, as indicated by the authors. The PC-VPC keeps the shape of the concentration-time profile even though the observations are not on their original scale, as in a typical VPC. However, the PC-VPC only accounts for differences in typical subject predictions; there may also be differences in expected variability around this prediction. Therefore, from a model evaluation perspective, the SVPC is a more accurate approach as each participant’s observations are compared to model-simulated concentrations based on his or her own design without any approximation in normalization. In addition, the SVPC also has the advantage of being able to provide a standard scale for all observations across time points for a clearer view of distribution comparison when observation values expand to several logs, as discussed previously.</p>
<p>Although we do not recommend it for model evaluation purposes, the distribution of observations in the context of the shape of the observation-time profile can be reconstructed by translating the observation percentiles (<italic>P</italic><sub><italic>i,j</italic></sub>) in the SVPC plot to their corresponding expected observation values obtained from simulated values following a typical design feature if users so desire. The steps for obtaining this plot are as follows: (1) simulate data for a large number of individuals (eg, 1000) using a typical design feature, such as typical dose, dosing schedule, and typical influential covariates; (2) construct an expected observation profile under this design feature for each individual by selecting a value from the 1000 simulated values based on his or her <italic>P</italic><sub><italic>i,j</italic></sub> value at each time point; and (3) plot the expected observations versus time and overlay them with the desired percentiles (eg, 5% and 95%) from the 1000 model-simulated data obtained from step 1. <xref ref-type="fig" rid="fig7-0091270010390040">Figures 7A</xref>,<xref ref-type="fig" rid="fig7-0091270010390040">B</xref> shows the reconstructed profile of observation distribution (<italic>P</italic><sub><italic>i,j</italic></sub> in the context of the shape of the profile) using simulation study 2 as an example. <xref ref-type="fig" rid="fig7-0091270010390040">Figures 7A</xref>,<xref ref-type="fig" rid="fig7-0091270010390040">B</xref> contains the same distribution information as in <xref ref-type="fig" rid="fig3-0091270010390040">Figures 3C</xref>,<xref ref-type="fig" rid="fig3-0091270010390040">D</xref> of the SVPC plot, respectively. As with the SVPC, we can identify the wrong model and the correct model from these plots. However, the differences between the 5th/95th percentiles of the reconstructed profile of the observation distribution and model-predicted distribution are less apparent compared to those in the SVPC plots. As discussed in simulation example 5, by normalizing observations to the scale 0 to 1 and transforming observation from a normal distribution (VPC and reconstructed profile of observation distribution) to a uniform distribution (SVPC), the deviation at each time point can be presented with equal clarity. It has also been well documented that it is easier to judge deviations along straight lines rather than curved lines.<sup><xref ref-type="bibr" rid="bibr16-0091270010390040">16</xref></sup> For these reasons, SVPC is a more powerful tool in detecting model misspecification compared to VPC and the reconstructed profile of observation distribution.</p>
<fig id="fig7-0091270010390040" position="float">
<label>Figure 7.</label>
<caption>
<p>The reconstructed observation distribution plots of simulation study 2. The so-called reconstructed time profiles of observation distribution for the model with incorrect (A) and correct (B) parameter estimates in simulation study 2 were obtained as follows: (1) simulate a large number of individuals (eg, 1000) using a typical design feature (body weight [BW] of all these individuals is 70 kg in this case), such as typical dose, dosing schedule, and typical influential covariates; (2) reproduce expected observations under this design feature for each individual by selecting a value from the 1000 simulated values based on that individual’s observation percentile value (P<sub>i,j</sub>) at each time point; and (3) plot the expected observations versus time and overlay them with the 5th, 50th, and 95th percentiles of model-simulated data obtained in step 1. Open circles, expected observation values; dashed line: 5th, 50th, and 95th percentiles (from bottom to top) of model-simulated data; dotted line, 5th, 50th, and 95th percentiles of the expected observations. PK, pharmacokinetic.</p>
</caption>
<graphic xlink:href="10.1177_0091270010390040-fig7.tif"/>
</fig>
</sec></sec>
<sec id="section29-0091270010390040">
<title>Conclusion</title>
<p>The typical VPC is a very useful tool in model evaluation. When appropriate, a VPC should be performed for the purpose of visual predictive check as it preserves the shape of the PK/PD versus time profile. However, the typical VPC is only applicable when PK/PD versus time profiles for all participants should be the same when all Ω and σ values are set to 0, unless data can be meaningfully stratified by influential covariates and/or study design.</p>
<p>The SVPC is a robust, complementary diagnostic tool to the typical VPC. It filters out all covariate effects and other study design differences and thus can be used in all cases where covariate effects exist and study design characteristics vary between participants and across time. In addition to the information provided by a typical VPC, the SVPC can be used to evaluate covariate effects and identify potential covariate effects over the time course. Situations when the typical VPC is not feasible while the SVPC can be used include but are not limited to the following:</p>
<list id="list1-0091270010390040" list-type="bullet">
<list-item><p>Patients received an individualized dose or there are a small number of patients per dose group and PK or PD is nonlinear (ie, observations cannot be dose-normalized).</p></list-item>
<list-item><p>Covariate effect(s) in the final model: There are multiple categorical covariate effects, such as demographics, treatment effects, disease conditions, concomitant medications, and food effect, on PK or PD parameters.</p></list-item>
<list-item><p>A covariate is a continuous variable, which makes stratification difficult or arbitrary.</p></list-item>
<list-item><p>Study design and execution vary among individuals, such as adaptive design, differences in dosing schedule, dose changes and dosing time that vary during the study, and protocol violations.</p></list-item>
</list>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Supplementary data for this article are available at <ext-link ext-link-type="uri" xlink:href="http://jcp.sagepub.com/supplemental/">http://jcp.sagepub.com/supplemental/</ext-link>.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The authors have no financial interests to disclose.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010390040">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chien</surname><given-names>JY</given-names></name>
<name><surname>Friedrich</surname><given-names>S</given-names></name>
<name><surname>Heathman</surname><given-names>MA</given-names></name>
<name><surname>de Alwis</surname><given-names>DP</given-names></name>
<name><surname>Sinha</surname><given-names>V</given-names></name>
</person-group>. <article-title>Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation</article-title>. <source>AAPS J</source>. <year>2005</year>;<volume>7</volume>:<fpage>E544</fpage>-<lpage>E559</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010390040">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lesko</surname><given-names>LJ</given-names></name>
<name><surname>Rowland</surname><given-names>M</given-names></name>
<name><surname>Peck</surname><given-names>CC</given-names></name>
<name><surname>Blaschke</surname><given-names>TF</given-names></name>
</person-group>. <article-title>Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans</article-title>. <source>Pharm Res</source>. <year>2000</year>;<volume>17</volume>:<fpage>1335</fpage>-<lpage>1344</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010390040">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sheiner</surname><given-names>LB</given-names></name>
<name><surname>Steimer</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Pharmacokinetic/pharmacodynamic modeling in drug development</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>2000</year>;<volume>40</volume>:<fpage>67</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010390040">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ette</surname><given-names>EI</given-names></name>
<name><surname>Williams</surname><given-names>PJ</given-names></name>
<name><surname>Kim</surname><given-names>YH</given-names></name>
<name><surname>Lane</surname><given-names>JR</given-names></name>
<name><surname>Liu</surname><given-names>MJ</given-names></name>
<name><surname>Capparelli</surname><given-names>EV</given-names></name>
</person-group>. <article-title>Model appropriateness and population pharmacokinetic modeling</article-title>. <source>J Clin Pharmacol</source>. <year>2003</year>;<volume>43</volume>:<fpage>610</fpage>-<lpage>623</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010390040">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Savic</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Diagnosing model diagnostics</article-title>. <source>Clin Pharmacol Ther</source>. <year>2007</year>;<volume>82</volume>:<fpage>17</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010390040">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holford</surname><given-names>N</given-names></name>
</person-group>. <article-title>The visual predictive check: superiority to standard diagnostic (Rorschach) plots</article-title>. <source>PAGE</source>. <year>2005</year>;<volume>14</volume>:<fpage>738</fpage>.</citation>
</ref>
<ref id="bibr7-0091270010390040">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yano</surname><given-names>Y</given-names></name>
<name><surname>Beal</surname><given-names>SL</given-names></name>
<name><surname>Sheiner</surname><given-names>LB</given-names></name>
</person-group>. <article-title>Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2001</year>;<volume>28</volume>:<fpage>171</fpage>-<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010390040">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brendel</surname><given-names>K</given-names></name>
<name><surname>Comets</surname><given-names>E</given-names></name>
<name><surname>Laffont</surname><given-names>C</given-names></name>
<name><surname>Laveille</surname><given-names>C</given-names></name>
<name><surname>Mentré</surname><given-names>F</given-names></name>
</person-group>. <article-title>Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide</article-title>. <source>Pharm Res</source>. <year>2006</year>;<volume>23</volume>:<fpage>2036</fpage>-<lpage>2049</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010390040">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Comets</surname><given-names>E</given-names></name>
<name><surname>Brendel</surname><given-names>K</given-names></name>
<name><surname>Mentré</surname><given-names>F</given-names></name>
</person-group>. <article-title>Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R</article-title>. <source>Comput Methods Programs Biomed</source>. <year>2008</year>;<volume>90</volume>:<fpage>154</fpage>-<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010390040">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mentré</surname><given-names>F</given-names></name>
<name><surname>Escolano</surname><given-names>S</given-names></name>
</person-group>. <article-title>Prediction discrepancies for the evaluation of nonlinear mixed-effects models</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2006</year>;<volume>33</volume>:<fpage>345</fpage>-<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010390040">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karlsson</surname><given-names>M</given-names></name>
<name><surname>Holford</surname><given-names>N</given-names></name>
</person-group>. <article-title>A tutorial on visual predictive checks</article-title>. <source>PAGE</source>. <year>2008</year>;<volume>17</volume>:<fpage>1434</fpage>.</citation>
</ref>
<ref id="bibr12-0091270010390040">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plummer</surname><given-names>R</given-names></name>
<name><surname>Jones</surname><given-names>C</given-names></name>
<name><surname>Middleton</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>:<fpage>7917</fpage>-<lpage>7923</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010390040">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Reilly</surname><given-names>RA</given-names></name>
<name><surname>Aggeler</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Studies on coumarin anticoagulant drugs: initiation of warfarin therapy without a loading dose</article-title>. <source>Circulation</source>. <year>1968</year>;<volume>38</volume>:<fpage>169</fpage>-<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010390040">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Reilly</surname><given-names>RA</given-names></name>
<name><surname>Aggeler</surname><given-names>PM</given-names></name>
<name><surname>Leong</surname><given-names>LS</given-names></name>
</person-group>. <article-title>Studies on the coumarin anticoagulant drugs: the pharmacodynamics of warfarin in man</article-title>. <source>J Clin Invest</source>. <year>1963</year>;<volume>42</volume>:<fpage>1542</fpage>-<lpage>1551</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010390040">
<label>15.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Bergstrand</surname><given-names>M</given-names></name>
<name><surname>Hooker</surname><given-names>AC</given-names></name>
<name><surname>Wallin</surname><given-names>JE</given-names></name>
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
</person-group>. <article-title>Prediction corrected visual predictive checks [abstract]. American Conference of Pharmacometrics (ACoP)</article-title> <year>2009</year>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.go-acop.org/acop2009/abstracts">http://www.go-acop.org/acop2009/abstracts</ext-link></comment>.</citation>
</ref>
<ref id="bibr16-0091270010390040">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cleveland</surname><given-names>WS</given-names></name>
<name><surname>McGill</surname><given-names>R</given-names></name>
</person-group>. <article-title>Graphical perception: the visual decoding of quantitative information on graphical displays of data</article-title>. <source>J R Stat Soc A (Gen)</source>. <year>1987</year>;<volume>150</volume>:<fpage>192</fpage>-<lpage>229</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>